Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sanofi has initiated a clinical study titled A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis. The study aims to assess the efficacy and safety of SAR442970, a drug intended for treating moderate to severe ulcerative colitis, over a period of up to 168 weeks.
The study tests SAR442970, administered subcutaneously, in two experimental dose regimens against a placebo. The primary goal is to determine the drug’s effectiveness in alleviating symptoms of ulcerative colitis.
This interventional study employs a randomized, parallel assignment model with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused.
The study began on July 7, 2025, with primary completion estimated within the study’s 168-week timeline. The latest update was submitted on July 16, 2025, indicating active recruitment.
The study’s progress could influence Sanofi’s stock performance, as successful outcomes may enhance investor confidence and market position in the competitive ulcerative colitis treatment landscape.
The study is ongoing, with further details accessible on the ClinicalTrials portal.